Dr. Krishnaiah Yellela of FDA\/CDER organized a course on \u201cProduct Quality of Transdermal Systems\u201d which Dr. Bozena Michniak-Kohn spoke at earlier this month. The venue was the FDA\u2019s White Oak campus in Silver Spring, MD.\u00a0 The White Oak campus of the FDA was impressive with many new buildings and excellent laboratory facilities and equipment.<\/p>\n
The plenary speaker was the well-known dermatologist Dr. Howard Maibach from USC San Francisco and speakers included academicians, practicing physicians as well as FDA scientists. Tours of the FDA DPQR laboratories were also on the two day agenda.<\/p>\n
Dr. Michniak-Kohn\u2019s topic was \u201cSkin Models for In Vivo Performance Testing of Transdermal Drug Delivery Systems\u201d.\u00a0 Dr. Michniak-Kohn was also a panelist during the afternoon discussion.<\/p>\n
In vitro methods are often preferred over in vivo for permeability testing of compounds in transdermal drug delivery systems due to lower costs, less variability in data and easier handling.\u00a0 Several approaches are being used including the use of human skin membranes, tissue engineered human skin models, as well as non-biological models. These models are useful for routing testing of transdermal formulations each with its limitations as well as benefits. Dr. Michniak-Kohn\u2019s presentation addressed the usefulness of several models and discussed how they can be applied to transdermal drug permeability testing.<\/p>\n","protected":false},"excerpt":{"rendered":"